FDA expands Stelara approval to children aged 2, intensifying biosimilar competition
AI Summary- FDA approved Stelara for ulcerative colitis patients aged 2 and older.
- 41% was Stelara’s annual revenue decline from 2024 to last year.
- Three South Korean biosimilars already hold adult Crohn’s disease and ulcerative colitis indications.